Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients
Open Access
- 18 April 2023
- journal article
- research article
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 18, e14
Abstract
Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between thrombotic and bleeding risks must be carefully weighed up when considering DPI. However, with the introduction of activated coagulation factor XI inhibitors, which have fewer bleeding effects, the use of DPI in patients with atherosclerotic cardiovascular diseases could be extended.Keywords
This publication has 11 references indexed in Scilit:
- A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial InfarctionCirculation, 2022
- Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic eventsEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2022
- The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EASTEP Europace, 2022
- Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyThe Lancet, 2022
- Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trialsEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2021
- Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2021
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2020
- Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary DiseaseNew England Journal of Medicine, 2019
- Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012